Abstract: Immune checkpoint inhibitors（CPIs）have obtained approval for the treatment of many kinds of malignant tumors，including melanoma，non-small cell lung cancer，et al. Recently，Keytruda（pembrolizumab）is indicated for the treatment of solid tumors that have been identified as microsatellite instability-high（MSI-H）tumors. Besides，these immune targeted agents also generate immune-related adverse events（irAEs），involving almost all organs，and differs much from side effects of conventional chemotherapy and targeted therapy. Although severe irAEs are rare，they can become life-threatening if not anticipated and managed appropriately，and management of irAEs are lack of sufficient evidence. We will review features，biomarkers and management of irAEs to provide referrence for clinical care of patients under CPIs.